Format
Sort by
Items per page

Send to

Choose Destination

Best matches for posaconazole/TU:

Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections. Clark NM et al. Semin Respir Crit Care Med. (2015)

Pharmacologic and clinical evaluation of posaconazole. Moore JN et al. Expert Rev Clin Pharmacol. (2015)

Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections. McKeage K et al. Drugs. (2015)

Search results

Items: 1 to 20 of 1290

1.
2.

Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach.

Hens B, Bermejo M, Tsume Y, Gonzalez-Alvarez I, Ruan H, Matsui K, Amidon GE, Cavanagh KL, Kuminek G, Benninghoff G, Fan J, Rodríguez-Hornedo N, Amidon GL.

Eur J Pharm Sci. 2018 Mar 30;115:258-269. doi: 10.1016/j.ejps.2018.01.039.

PMID:
29378253
3.

Refractory bronchovascular pleuropulmonary mucormycosis: Case report and difficulties in management.

Manjunath M, Prajapat D, Sharma RK, Talwar D.

Lung India. 2018 Jan-Feb;35(1):70-72. doi: 10.4103/lungindia.lungindia_535_16.

4.

Alternative approaches to the therapeutic drug monitoring of prophylactic posaconazole in haematology patients.

Vyzantiadis TA, Yannaki E, Oliver DA, Markantonatou AM, Boussiou Z, Louka A, Zachrou E, Johnson EM.

J Mycol Med. 2018 Jan 6. pii: S1156-5233(17)30098-7. doi: 10.1016/j.mycmed.2017.12.005. [Epub ahead of print]

PMID:
29317184
5.

Posaconazole tablets in real life lung transplantation: impact on exposure, drug-drug interactions and drug management in lung transplanted patients, including cystic fibrosis.

Launay M, Roux A, Beaumont L, Douvry B, Lecuyer L, Douez E, Picard C, Grenet D, Jullien V, Boussaud V, Guillemain R, Billaud EM.

Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.02061-17. doi: 10.1128/AAC.02061-17. [Epub ahead of print]

PMID:
29311077
6.

Use of Intravenous Posaconazole in Hematopoietic Stem Cell Transplant Patients.

Strommen A, Hurst AL, Curtis D, Abzug MJ.

J Pediatr Hematol Oncol. 2018 Jan 5. doi: 10.1097/MPH.0000000000001071. [Epub ahead of print]

PMID:
29309375
7.

The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer.

Wasko JA, Ustun C, Birkenbach M, Faizer R, Green JS.

J Oncol Pharm Pract. 2017 Jan 1:1078155217748471. doi: 10.1177/1078155217748471. [Epub ahead of print]

PMID:
29285995
8.

Azole-resistant and -susceptible Aspergillus fumigatus isolates show comparable fitness and azole treatment outcome in immunocompetent mice.

Lackner M, Rambach G, Jukic E, Sartori B, Fritz J, Seger C, Hagleitner M, Speth C, Lass-Flörl C.

Med Mycol. 2017 Dec 8. doi: 10.1093/mmy/myx109. [Epub ahead of print]

PMID:
29228287
9.

Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Löhnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA.

Ann Hematol. 2018 Feb;97(2):197-207. doi: 10.1007/s00277-017-3196-2. Epub 2017 Dec 7. Review.

10.

Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.

Jeong W, Snell GI, Levvey BJ, Westall GP, Morrissey CO, Wolfe R, Ivulich S, Neoh CF, Slavin MA, Kong DCM.

J Antimicrob Chemother. 2017 Dec 2. doi: 10.1093/jac/dkx440. [Epub ahead of print]

PMID:
29211913
11.

Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies.

Suh HJ, Kim I, Cho JY, Park SI, Yoon SH, Hwang JH, Bae JY, Lee JO, Koh Y, Song KH, Choe PG, Yu KS, Kim ES, Kim HB, Bang SM, Kim NJ, Song SH, Park WB, Oh MD.

Ther Drug Monit. 2018 Feb;40(1):115-119. doi: 10.1097/FTD.0000000000000469.

PMID:
29189664
12.

Cutaneous mucormycosis.

Castrejón-Pérez AD, Welsh EC, Miranda I, Ocampo-Candiani J, Welsh O.

An Bras Dermatol. 2017 May-Jun;92(3):304-311. doi: 10.1590/abd1806-4841.20176614. Review.

13.

First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease.

Ramírez JC, Parrado R, Sulleiro E, de la Barra A, Rodríguez M, Villarroel S, Irazu L, Alonso-Vega C, Alves F, Curto MA, García L, Ortiz L, Torrico F, Gascón J, Flevaud L, Molina I, Ribeiro I, Schijman AG.

PLoS One. 2017 Nov 27;12(11):e0188550. doi: 10.1371/journal.pone.0188550. eCollection 2017.

14.

Colonic basidiobolomycosis with liver involvement masquerading as gastrointestinal lymphoma: a case report and literature review.

Zekavat OR, Abdolkarimi B, Pouladfar G, Fathpour G, Mokhtari M, Shakibazad N.

Rev Soc Bras Med Trop. 2017 Sep-Oct;50(5):712-714. doi: 10.1590/0037-8682-0057-2017. Review.

15.

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection.

Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicolò A, Cusato J, Di Perri G, D'Avolio A.

Biomedicines. 2017 Nov 20;5(4). pii: E66. doi: 10.3390/biomedicines5040066.

16.

Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.

Peterlin P, Chauvin C, Le Gouill S, Pere M, Dalichampt M, Guillaume T, Garnier A, Paré M, Le Bourgeois A, Moreau P, Chevallier P, Deslandes G, Gastinne T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01746-17. doi: 10.1128/AAC.01746-17. Print 2018 Feb.

PMID:
29133564
17.

Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.

Hoenigl M, Prattes J, Neumeister P, Wölfler A, Krause R.

Mycoses. 2018 Mar;61(3):201-205. doi: 10.1111/myc.12727. Epub 2017 Nov 22.

18.

Posaconazole liquid vs tablet formulation in lung transplant recipients.

Stelzer D, Weber A, Ihle F, Matthes S, Ceelen F, Zimmermann G, Kneidinger N, Schramm R, Winter H, Zoller M, Vogeser M, Behr J, Neurohr C.

Mycoses. 2018 Mar;61(3):186-194. doi: 10.1111/myc.12724. Epub 2017 Nov 22.

PMID:
29110351
19.

Risk factors for subtherapeutic levels of posaconazole tablet.

Tang LA, Marini BL, Benitez L, Nagel JL, Miceli M, Berglund C, Perissinotti AJ.

J Antimicrob Chemother. 2017 Oct 1;72(10):2902-2905. doi: 10.1093/jac/dkx228.

PMID:
29091205
20.

Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.

Amsden JR, Gubbins PO.

Expert Opin Drug Metab Toxicol. 2017 Nov;13(11):1135-1146. doi: 10.1080/17425255.2017.1391213. Epub 2017 Oct 20. Review.

PMID:
29022838

Supplemental Content

Loading ...
Support Center